NORTHERN-BITCOIN-AG
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87), one of the largest blockchain solutions and datacenter providers in the world and Canaan Inc, (Nasdaq: CAN, US ISIN: US1347481020) one of the leading blockchain technology companies in the world are happy to announce the beginning of close cooperation in the areas of Artificial Intelligence (AI) development, Blockchain Technology and Datacenter operations.
Combining Canaan's excellence in the fields of AI Chip development and ASIC hardware with Northern Data's proven track record at delivering A class Datacenter and Blockchain infrastructure at scale will provide both companies with a solid bedrock to build and expand in this tremendously exciting technology space and catapult both companies together to new heights.
With Northern Data's North American and European teams and facilities working in concert with Canaan's advanced R&D teams in Asia, this first step towards a strategic partnership should unlock many additional synergistic projects throughout the blockchain and technology sectors.
"We are able to unlock massive potential in some of the fastest-growing industries with this strategic cooperation," says Aroosh Thillainathan, CEO of Northern Data AG. "Canaan is a technical leader in AI and Blockchain Technology and showed an impressive growth over the past few years. We are very excited about our partnership and see a huge upside for both companies."
"Northern Data has rich experience in building high-performance computing infrastructure," says NG Zhang CEO of Canaan, "and our research and development (R&D) team is collaborating with Northern Data. Both sides have achieved positive results. In addition, Northern Data will provide computational resources support for our overseas R&D in the US. Canaan looks forward to further cooperation in product development, AI, and high-performance computing with Northern Data in the future."
For Northern Data AG, the strategic cooperation with Canaan, Inc. is one of the first of a series of many partnerships with the world's leading players in AI and Blockchain-Technology that are about to be signed over the upcoming months.
About Canaan, Inc:
Canaan is a leading supercomputing solution provider through its proprietary high-performance computing ASICs. It is dedicated to the availability of supercomputing to everyone, the widespread application of blockchain and AI, and the improvement of social efficiency and people's life. In 2018, Canaan made two major technological breakthroughs, namely mass-producing the first BTC 7nm chip, and being one of the first to deliver commercial edge computing AI chips on RISC-V architecture, now used in access control, smart door locks. Canaan produced in aggregate over 150 million ASICs in 2017, 2018 and the nine months ended September 30, 2019. At the same time, Canaan was the second largest manufacturer of Bitcoin mining machines in the world. On 21st November 2019, Canaan was listed on NASDAQ, making it the first listed company in the Chinese blockchain industry, and the first Chinese AI chips company with independent intellectual property to successfully IPO in the U.S.
About Northern Data:
Northern Data AG is building a global infrastructure for the field of High-Performance Computing (HPC), which goes far beyond Bitcoin and blockchain applications. The globally operating technology Company evolves from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and specializes in the infrastructure for blockchain applications, such as Bitcoin mining. For this purpose, the Company offers solutions both stationary in large data centers and in mobile containers, which can be located at any location worldwide. In doing so, it combines self-developed software and hardware with intelligent concepts for sustainable energy supply. In Texas, Whinstone is currently building the largest data center in the USA and, at the same time, the world's largest Bitcoin mining facility. The HPC data center infrastructure built by Northern Data Group is designed to be used not only for blockchain applications but also for numerous other industries, such as game streaming, artificial intelligence, and autonomous driving.
Disclaimer: This press release represents neither an offer to sell nor a request to submit an offer to purchase Northern Data AG securities; nor does it constitute a securities prospectus for Northern Data AG. The information contained in this press release is not intended to serve as a basis for financial, legal, tax-related or other business decisions. Investment or other decisions should not be taken solely on the basis of this press release. As in all business and investment matters, please seek qualified professional advice. This press release and the information it contains are not intended for direct or indirect communication to or within the United States of America, Canada, Australia or Japan.
| Language: | English |
| Company: | Northern Bitcoin AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northernbitcoin.com |
| Internet: | www.northernbitcoin.com |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate |
| Exchange | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200218006230/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom